Item request has been placed! ×
Item request cannot be made. ×
loading  Processing Request

Clinical Outcomes with Alternative Dosing Strategies for Piperacillin/Tazobactam: A Systematic Review and Meta-Analysis

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
  • معلومة اضافية
    • Contributors:
      Zhang, C (reprint author), Peking Univ, Dept Pharm, Hosp 3, Beijing 100871, Peoples R China.; Peking Univ, Dept Pharm, Hosp 3, Beijing 100871, Peoples R China.; Peking Univ, Sch Pharmaceut Sci, Beijing 100871, Peoples R China.; First Peoples Hosp, Dept Pharm, Lianyungang, Jiangsu, Peoples R China.
    • بيانات النشر:
      plos one
    • الموضوع:
      2015
    • Collection:
      Peking University Institutional Repository (PKU IR) / 北京大学机构知识库
    • نبذة مختصرة :
      Objectives A better dosing strategy can improve clinical outcomes for patients. We sought to compare the extended or continuous infusion with conventional intermittent infusion of piperacillin/ tazobactam, investigating which approach is better and worthy of recommendation for clinical use. Methods Articles were gathered from PubMed, Web of Science, ProQuest, Science Direct, Cochrane, two Chinese literature databases (CNKI, Wan Fang Data) and related ICAAC and ACCP conferences. Randomized controlled and observational studies that compared extended or continuous infusion with conventional intermittent infusion of piperacillin/ tazobactam were identified from the databases above and analyzed. Two reviewers independently extracted and investigated the data. A meta-analysis was performed using Revman 5.2 software. The quality of each study was assessed. Sensitivity analysis and publication bias were evaluated. Results Five randomized controlled trials and nine observational studies were included in this study. All included studies had high quality and no publication bias was found. Compared to the conventional intermittent infusion approach, the extended or continuous infusion group had a significantly higher clinical cure rate (OR 1.88, 95% CI 1.29-2.73, P = 0.0009) and a lower mortality rate (OR 0.67, 95% CI 0.50-0.89, P = 0.005). No statistical difference was observed for bacteriologic cure (OR 1.40, 95% CI 0.82-2.37, P = 0.22) between the two dosing regimens. The sensitivity analysis showed the results were stable. Conclusions Our systematic review and meta-analysis suggested that the extended or continuous infusion strategy of piperacillin/tazobactam should be recommended for clinical use considering its higher clinical cure rate and lower mortality rate in comparison with conventional intermittent strategy. Data from this study could be extrapolated for other beta-lactam antimicrobials. Therefore, this dosing strategy could be considered in clinical practice. ; Multidisciplinary Sciences ; SCI(E) ; PubMed ; 0 ...
    • ISSN:
      1932-6203
    • Relation:
      PLOS ONE.2015,10,(1).; 651131; http://hdl.handle.net/20.500.11897/156289; WOS:000348168100008
    • الرقم المعرف:
      10.1371/journal.pone.0116769
    • الرقم المعرف:
      edsbas.E3B6E736